Dr. Haber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
149 7202
Boston, MA 02114Phone+1 617-726-7805Fax+1 617-724-6919
Education & Training
Massachusetts Institute of TechnologyPost-Doctoral Fellowship, 1987 - 1991
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1990
Massachusetts General HospitalResidency, Internal Medicine, 1984 - 1986- Massachusetts General HospitalInternship, Internal Medicine, 1983 - 1984
Stanford University School of MedicineClass of 1983
Certifications & Licensure
MA State Medical License 1985 - 2027- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member Fellow of the AACR Academy, 2019
- Elected Member National Academy of Sciences, 2018
- Investigator Howard Hughes Medical Institute
- Join now to see all
Publications & Presentations
PubMed
- Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.Avanish Mishra, Shih-Bo Huang, Taronish Dubash, Risa Burr, Jon F Edd
Nature Communications. 2025-01-02 - Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer.Daniel A Haber, Steven J Skates
Cancer Discovery. 2024-11-01 - 1 citationsDevelopmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.Risa Burr, Ignaty Leshchiner, Christina L Costantino, Martin Blohmer, Tilak Sundaresan
Nature Cancer. 2024-11-01
Journal Articles
- A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast CancerDavid T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research
Press Mentions
Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in MelanomaMarch 16th, 2023- Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis SuppressionOctober 24th, 2022
- TellBio’s Scientific Founders Publish Very High Concordance Between CTCs and ctDNA from Liquid Biopsies in Patients with Breast CancerJuly 15th, 2021
- Join now to see all
Grant Support
- Circumventing Acquired Resistance To Growth Factor Receptor Kinase InhibitorsNational Cancer Institute2008–2012
- Data Production, And Informatics And IntegrationNational Human Genome Research Institute2010–2011
- P1 - Clinical Correlations Of WTX Inactivation In Wilms TumorNational Cancer Institute2010–2011
- Functional Properties Of The Wilms'Tumor Gene WT1National Cancer Institute2008–2011
- Functional Properties Of The Wilms' Tumor Gene WT1National Cancer Institute2010
- Clinical Correlations Of WTX Inactivation In Wilms TumorNational Cancer Institute2009
- Functional Properties Of The Wilm'S Tumor Gene WT1National Cancer Institute2003–2007
- Targets Of Ewing Sarcoma-Wilms Tumor 1 OncoproteinNational Cancer Institute2002–2006
- Genetic Models Of Cellular ProliferationNational Cancer Institute2002–2006
- Functional Characterization Of BRCA1National Cancer Institute2000–2004
- Screen For Genes Targeted By Homozygous Deletion During Cancer ProgressionNational Cancer Institute2002
- G2 Checkpoint Genes In Breast Cancer SusceptibiityNational Cancer Institute2000–2002
- Functional Properties Of The Wilms Tumor Gene WT1National Cancer Institute1998–2002
- Mutational Analysis Of P53 Related GenesNational Cancer Institute2000–2001
- Isolation Of Gene For X-Linked LymphoproliferationNational Cancer Institute1995–1998
- Mutational And Functional Analysis Of Wilm'S TumorNational Cancer Institute1994–1997
- Mutational And Functional Analysis Of Wilms'TumorNational Cancer Institute1993
- Multidrug Resistance Genes--Expression And FunctionNational Cancer Institute1990
- Multidrug Resistance Genes--Expression And FunctionNational Cancer Institute1988–1989
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
